Eberhard Schulz

Eberhard Schulz

Auto-generated profile, based on publicly available information

Eberhard Schulz

Department of Cardiology, General Hospital Celle , Siemensplatz 4, Celle 29223

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2005 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
MWMaria C. Wendt
Maria C. Wendt
Andreas DaiberAndreas Daiber
Andreas Daiber
AKAndrei L. Kleschyov
Andrei L. Kleschyov
AMAlexander Mülsch
Alexander Mülsch
KSKarsten Sydow
Karsten Sydow
TMThomas Münzel
Thomas Münzel

1 September 2021 in Nitric Oxide
Verified
Journal Article
Open access
PSPaul Stamm
Paul Stamm
MOMatthias Oelze
Matthias Oelze
SSSebastian Steven
Sebastian Steven
SKSwenja Kröller-Schön
Swenja Kröller-Schön
MKMiroslava Kvandova
Miroslava Kvandova
Thomas MuenzelThomas Muenzel
Thomas Muenzel
Arterial hypertension is one of the major health risk factors leading to coronary artery disease, stroke or peripheral artery disease. Dietary uptake of inorganic nitrite (NO2-) and nitrate (NO3-) via vegetables leads to enhanced vascular NO bioavailability and provides antihypertensive effects. The present study aims to understand the underlying vasoprotective effects of nutritional NO2- and NO3- co-therapy in mice with angiotensin-II (AT-II)-induced arterial hypertension. High-dose AT-II (1 mg/kg/d, 1w, s. c.) was used to induce arterial hypertension in male C57BL/6 mice. Additional inorganic nitrite (7.5 mg/kg/d, p. o.) or nitrate (150 mg/kg/d, p. o.) were administered via the drinking water. Blood pressure (tail-cuff method) and endothelial function (isometric tension) were determined. Oxidative stress and inflammation markers were quantified in aorta, heart, kidney and blood. Co-treatment with inorganic nitrite, but not with nitrate, normalized vascular function, oxidative stress markers and inflammatory pathways in AT-II treated mice. Of note, the highly beneficial effects of nitrite on all parameters and the less pronounced protection by nitrate, as seen by improvement of some parameters, were observed despite no significant increase in plasma nitrite levels by both therapies. Methemoglobin levels tended to be higher upon nitrite/nitrate treatment. Nutritional nitric oxide precursors represent a non-pharmacological treatment option for hypertension that could be applied to the general population (e.g. by eating certain vegetables). The more beneficial effects of inorganic nitrite may rely on superior NO bioactivation and stronger blood pressure lowering effects. Future large-scale clinical studies should investigate whether hypertension and cardiovascular outcome in general can be influenced by dietary inorganic nitrite therapy.

4 February 2004 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
AKA. Kuntz
A. Kuntz
HCH.-W. Clement
H.-W. Clement
WLW. Lehnert
W. Lehnert
DCD. van Calker
D. van Calker
KHK. Hennighausen
K. Hennighausen
ESE. Schulz
E. Schulz

1 June 2018 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
KEKatharina Ebert
Katharina Ebert
EMElena Maurice
Elena Maurice
RLRichard Lukačin
Richard Lukačin
CFChristian Fleischhaker
Christian Fleischhaker
ESEberhard Schulz
Eberhard Schulz
HCHans-Willi Clement
Hans-Willi Clement
Background: Therapeutic drug monitoring has become increasingly important in psychiatric therapy. However, it is not yet implemented as a daily routine in clinical settings. To evaluate new, noninvasive procedures, we compared blood and saliva venlafaxine, quetiapine, and citalopram concentrations in samples collected from psychiatric patients.Methods: We collected blood and saliva samples from 75 psychiatric patients (39 venlafaxine, 19 quetiapine, and 17 citalopram). Saliva sampling was achieved by the use of cotton pads. Venlafaxine (and its metabolite O-desmethylvenlafaxine) and quetiapine were analyzed by LC-MS/MS, whereas citalopram was analyzed by HPLC.Results: We observed significant correlations between concentrations of venlafaxine (ratio saliva/serum ± SD: 18.3 ± 9.5,P< 0.01, r = 0.895) and its metabolite O-desmethylvenlafaxine (ratio saliva/serum ± SD: 4.1 ± 3.2,P< 0.05, r = 0.344), quetiapine (ratio saliva/serum ± SD: 0.2 ± 0.2,P< 0.01, r = 0.935), and citalopram (ratio saliva/serum ± SD: 2.6 ± 1.2,P< 0.05, r = 0.54) in serum and in saliva. Furthermore, measured concentrations of venlafaxine (and its metabolite O-desmethylvenlafaxine) and citalopram were higher in saliva than in serum, whereas measured concentrations of quetiapine were higher in serum than in saliva.Conclusions: Using cotton pad saliva sampling, venlafaxine and quetiapine demonstrate high correlations between saliva and serum concentrations, whereas for O-desmethylvenlafaxine and citalopram, other methods of sampling might be preferable. Saliva therapeutic drug monitoring of psychoactive drugs might become a useful approach to achieving individual treatment regimens.

11 January 2021 in Open Heart
Verified
Journal Article
Open access
PDF file
ALAlexander Lauten
Alexander Lauten
TRTanja Rudolph
Tanja Rudolph
DMDavid Messika-Zeitoun
David Messika-Zeitoun
JTJeetendra Thambyrajah
Jeetendra Thambyrajah
ASAntonio Serra
Antonio Serra
Richard SteedsRichard Steeds
Richard Steeds
Objective Approximately 3.4% of adults aged >75 years suffer from aortic stenosis (AS). Guideline indications for aortic valve replacement (AVR) distinguish between patients with symptomatic and asymptomatic severe AS. The present analysis aims to assess contemporary practice in the treatment of severe AS across Europe and identify characteristics associated with treatment decisions, namely denial of AVR in symptomatic patients and assignment of asymptomatic patients to AVR. Methods Participants of the prospective, multinational IMPULSE database of patients with severe AS were grouped according to AS symptoms, and stratified into subgroups based on assignment to/denial of AVR. Results Of 1608 symptomatic patients, 23.8% did not undergo AVR and underwent medical treatment. Denial was independently associated with multiple factors, including severe frailty (p=0.024); mitral (p=0.002) or tricuspid (p=0.004) regurgitation grade III/IV, and the presence of renal impairment (p=0.017). Of 392 asymptomatic patients, 86.5% had no prespecified indication for AVR. Regardless, 36.3% were assigned to valve replacement. Those with an indexed aortic valve area (AVA; p=0.045) or left ventricular ejection fraction (LVEF; p<0.001) below the study median; or with a left ventricular end systolic diameter above the study median (p=0.007) were more likely to be assigned to AVR. Conclusions There may be considerable discrepancies between guideline-based recommendations and clinical practice decision-making in the treatment of AS. It appears that guidelines may not fully capture the complete clinical spectrum of patients with AS. Thus, there is a need to find ways to increase their acceptance and the rate of adoption.

7 September 2010 in ADHD Attention Deficit and Hyperactivity Disorders
Verified
Journal Article
Closed access
PDF file
ESEberhard Schulz
Eberhard Schulz
CFChristian Fleischhaker
Christian Fleischhaker
KHKlaus Hennighausen
Klaus Hennighausen
PHPhilip Heiser
Philip Heiser
FHFrank Haessler
Frank Haessler
JKJan Klatt
Jan Klatt